FCCC LOGO Faculty Publications
Wang TP , Scott JH , Barta SK
The evolving role of targeted biological agents in the management of indolent B-cell lymphomas
Ther Adv Hematol. 2017 Dec;8(12) :329-344
PMID: 29204260    PMCID: PMC5703116   
Back to previous list
Abstract
Improved understanding of the mechanisms of lymphomagenesis has resulted in a surge of development for new targeted agents. An impressive number of biological agents targeting different steps in the pathways of tumor proliferation, survival and apoptosis have become available. The management of patients with indolent non-Hodgkin lymphomas (iNHLs) is rapidly transforming with incorporation of those targeted biological agents into the front-line and relapsed/refractory setting. This review highlights several categories of novel biological agents and will discuss their potential role in the contemporary management of patients with iNHLs.
Notes
Wang, Trent Peng Scott, John Harwood Barta, Stefan Klaus Journal Article Review England Ther Adv Hematol. 2017 Dec;8(12):329-344. doi: 10.1177/2040620717738740. Epub 2017 Nov 22.